drugset / Trial / NCT03192735

Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer

NCT03192735 ↗

Phase 2 Unknown 50 enrolled Chang-Ming Huang, Prof.
NaSingle-groupOpen-labelTreatment

Summary

We star a multicentre, one-armed, clinical pilot trial intends to investigate the safety and effectiveness of Apatinib Combined With Oxaliplatin, Gimeracil and Oteracil Porassium Capsules Neoadjuvant Ttherapy for Locally Advanced Gastric Cancer(cT2-4/N+M0)

Timeline

Start
2017-09-01
Primary completion
2019-11-11
Completion
2024-12-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Gimeracil and Oteracil Unknown 40 mg Oral
Subject Gimeracil and Oteracil Unknown 50 mg Oral
Subject Gimeracil and Oteracil Unknown 60 mg Oral
Subject Oxaliplatin Small molecule 130 mg/m2 Intravenous
Subject Rivoceranib Small molecule 500 mg Oral

Indications